Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
1996

Study of Carboplatin in High-Dose Chemotherapy

Sample size: 31 publication Evidence: moderate

Author Information

Author(s): LJC van Warmerdam, S Rodenhuis, E van der Wall, RAA MaeS, JH Beijnen

Primary Institution: Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute

Hypothesis

What is the relationship between carboplatin exposure and toxicity in high-dose chemotherapy?

Conclusion

The pharmacokinetics of carboplatin in high-dose regimens are similar to those at conventional doses, with ototoxicity being the main dose-limiting factor.

Supporting Evidence

  • The study involved 200 treatment days and measured the area under the carboplatin plasma concentration curve.
  • Inter-patient variability in pharmacokinetics was reduced from 21% to 15% using the Calvert formula.
  • Ototoxicity was strongly related to the cumulative carboplatin AUC and was the principal dose-limiting toxicity.

Takeaway

This study looked at how carboplatin affects patients when given in high doses, finding that it can be safe but may cause hearing problems.

Methodology

Patients received high-dose carboplatin, cyclophosphamide, and thiotepa for four days, followed by stem cell transplantation, with pharmacokinetics assessed through plasma concentration measurements.

Potential Biases

Potential bias due to the specific patient selection criteria and the influence of prior treatments.

Limitations

The study had a small sample size and was limited to specific cancer types.

Participant Demographics

Patients included those with metastatic breast cancer, germ cell cancer, ovarian cancer, and childhood tumors, with a median age of 37 years.

Statistical Information

P-Value

0.007

Statistical Significance

p=0.007

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication